RT Journal Article
SR Electronic
T1 High prevalence of somatic <em>PIK3CA</em> and <em>TP53</em> pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.27.21263863
DO 10.1101/2021.09.27.21263863
A1 Anna Kostecka
A1 Tomasz Nowikiewicz
A1 Paweł Olszewski
A1 Magdalena Koczkowska
A1 Monika Horbacz
A1 Monika Heinzl
A1 Maria Andreou
A1 Renato Salazar
A1 Theresa Mair
A1 Piotr Madanecki
A1 Magdalena Gucwa
A1 Hanna Davies
A1 Jarosław Skokowski
A1 Patrick G. Buckley
A1 Rafał Pęksa
A1 Ewa Śrutek
A1 Łukasz Szylberg
A1 Johan Hartman
A1 Michał Jankowski
A1 Wojciech Zegarski
A1 Irene Tiemann-Boege
A1 Jan P. Dumanski
A1 Arkadiusz Piotrowski
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.27.21263863.abstract
AB The mammary gland undergoes hormonally stimulated cycles of proliferation, lactation and involution. We hypothesized that these factors increase the mutational burden in glandular tissue and may explain high cancer incidence rate in the general population and recurrent disease. Hence, we investigated the DNA sequence variants in the normal mammary gland, tumor and peripheral blood from 52 reportedly sporadic breast cancer patients, including breast-conserving surgery cases. Targeted resequencing of 542 cancer associated genes revealed mosaic somatic pathogenic variants of: PIK3CA, TP53, AKT1, MAP3K1, CDH1, RB1, NCOR1, MED12, CBFB, TBX3 and TSHR in the normal mammary gland, at considerable allelic frequencies (9×10−2 to 5.2×10−1) indicating clonal expansion. Further evaluation of the frequently damaged PIK3CA and TP53 genes by ultra-sensitive duplex sequencing demonstrated a diversified picture of multiple low level-mosaic (in 10−2 to 10−4 alleles) hotspot pathogenic variants. Our results raise a question about the oncogenic potential in non-tumor mammary gland tissue of breast-conserving surgery patients.Competing Interest StatementJPD is cofounder and shareholder in Cray Innovation AB. The remaining authors have declared that no competing interests exist.Funding StatementThis work was supported by the National Science Center, Poland grant (award no. UMO-2015/19/B/NZ2/03216) to AP and partially funded by the Foundation for Polish Science (FNP) under the International Research Agendas Program (grant number MAB/2018/6) to JPD and AP, co-financed by the European Union under the European Regional Development Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research described in the manuscript was approved by the bioethics committee at the Medical University of Gdansk (MUG).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw microarray data are in the process of submission to EGA; https://ega-archive.org/ (accession no. will be available upon publication). Next generation sequencing and duplex sequencing data are in the process of submission to EGA (accession no. will be available upon publication).